Pluri Inc. Common Stock
$1.14
-$0.03 (-2.91%)
$1.10Day Range$1.29
Key Statistics
Market Cap
$14.50M
Shares Outstanding
12.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 9, 1991
Round Lot
100
Locale
US
Trading Data
Day Open
$1.19
Day High
$1.29
Day Low
$1.10
Volume
30.8K
VWAP
$1.17
Prev Close
$1.17
Transactions
--
Acc. Volume
--
About Pluri Inc. Common Stock
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836113 employeesMATAM ADVANCED TECHNOLOGY PARK, HAIFA972-74-710-7171IPO Oct 9, 1991US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001158780
- Composite FIGI
- BBG000DQX509
- Share Class FIGI
- BBG001S8QJB7
- Ticker Root
- PLUR
- SIC Code
- 2836
About Pluri Inc. Common Stock (PLUR) Stock
Pluri Inc. Common Stock (PLUR) closed the 2026-09-16 session at $1.14, down 2.91% versus the previous close (-0.03). The stock opened at $1.19 and traded between $1.10 and $1.29 during that session. Session trading volume was 31K shares. The volume-weighted average price (VWAP) is $1.17.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Pluri Inc. Common Stock has a market capitalization of $14.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. PLUR is listed on the XNAS exchange. The company employs approximately 113 people. The recorded listing date is 1991-10-09.
On this page you can find market PLUR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.